<DOC>
	<DOCNO>NCT00049582</DOCNO>
	<brief_summary>This phase I trial study side effect best dose decitabine treating patient myelodysplastic syndrome acute myeloid leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Decitabine Treating Patients With Myelodysplastic Syndromes Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose decitabine patient high-risk myelodysplastic syndrome acute myeloid leukemia . II . Determine minimum effective dose drug produce demethylation DNA tolerable toxicity patient . III . Determine minimum effective dose drug augments vitro response retinoids . IV . Determine pharmacokinetics drug patient . V. Determine clinical response rate patient treat drug . OUTLINE : This dose-escalation , multicenter study . Patients receive decitabine IV 3 hour twice daily OR IV 1 hour daily day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos decitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A maximum 36 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>One follow diagnosis : Highrisk myelodysplastic syndrome ( MDS ) Acute myeloid leukemia ( AML ) De novo , secondary , relapsed disease Any number prior regimen primary relapsed disease Ineligible refuse aggressive management Measurable disease , define : More 5 % blast bone marrow patient MDS More 30 % blast bone marrow patient AML Involvement cerebrospinal fluid allow Performance status ECOG 02 Performance status Karnofsky 60100 % See Disease Characteristics Bilirubin great 1.25 time upper limit normal ( ULN ) AST and/or ALT great 1.25 time ULN Creatinine le 1.7 mg/dL Creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No ongoing active infection No uncontrolled illness would preclude study participation No psychiatric illness social situation would preclude study compliance No prior allergic reaction compound similar chemical biological composition decitabine No active malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception At least 4 week since prior biologic therapy ( e.g. , interferon , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , thrombopoietin , epoetin alfa ) No concurrent hematopoietic growth factor ( GMCSF , thrombopoietin , epoetin alfa ) No concurrent prophylactic GCSF Prior intrathecal cytarabine allow patient cerebrospinal fluid involvement At least 4 week since prior chemotherapy ( except lowdose chemotherapy administer maintain WBC count ) ( 6 week nitrosoureas mitomycin ) recover At least 24 hour since prior hydroxyurea Concurrent intrathecal cytarabine allow patient cerebrospinal fluid involvement No prior radiotherapy great 3,000 cGy marrowproducing area At least 4 week since prior radiotherapy recover Prior investigational therapy allow No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>